PE20160789A1 - Composiciones y metodos para admistracion de una enzima a las vias respiratorias de un sujeto - Google Patents
Composiciones y metodos para admistracion de una enzima a las vias respiratorias de un sujetoInfo
- Publication number
- PE20160789A1 PE20160789A1 PE2016000563A PE2016000563A PE20160789A1 PE 20160789 A1 PE20160789 A1 PE 20160789A1 PE 2016000563 A PE2016000563 A PE 2016000563A PE 2016000563 A PE2016000563 A PE 2016000563A PE 20160789 A1 PE20160789 A1 PE 20160789A1
- Authority
- PE
- Peru
- Prior art keywords
- compositions
- subject
- methods
- respiratory tract
- enzyme
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Metodos y composiciones para administracion de enzimas a las vias respiratorias de un sujeto. En algunos aspectos, se brinda la composicion nebulizada de enzimas, como activadores de plasminogenos. En aun otros aspectos, se brindan composiciones de perfluorocarbono que comprenden enzimas, como activadores de plasminogenos. Las composiciones, en algunos aspectos, pueden utilizarse para el tratamiento de infecciones pulmonares o lesion pulmonar aguda, como lesion pulmonar aguda inducida por inhalacion de humo (LPAIH).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361899739P | 2013-11-04 | 2013-11-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20160789A1 true PE20160789A1 (es) | 2016-08-17 |
Family
ID=53005414
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2016000563A PE20160789A1 (es) | 2013-11-04 | 2014-11-04 | Composiciones y metodos para admistracion de una enzima a las vias respiratorias de un sujeto |
Country Status (11)
Country | Link |
---|---|
US (2) | US20160279209A1 (es) |
EP (1) | EP3065705A4 (es) |
JP (1) | JP2016535782A (es) |
KR (1) | KR20160078986A (es) |
CN (1) | CN105764488A (es) |
AU (1) | AU2014341862A1 (es) |
CA (1) | CA2928759A1 (es) |
CL (1) | CL2016001062A1 (es) |
MX (1) | MX2016005720A (es) |
PE (1) | PE20160789A1 (es) |
WO (1) | WO2015066664A2 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6603207B2 (ja) | 2013-03-15 | 2019-11-06 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | ヌトリン3aおよびペプチドを用いた肺線維症の阻害 |
JP7496826B2 (ja) | 2018-09-10 | 2024-06-07 | ラング セラピューティクス,エルエルシー | Cav-1タンパク質の修飾ペプチドフラグメント及び線維症の治療におけるその使用 |
WO2021180068A1 (zh) * | 2020-03-09 | 2021-09-16 | 泰伦基国际有限公司 | 一种治疗2019新型冠状病毒引发疾病的方法和药物 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4790305A (en) * | 1986-06-23 | 1988-12-13 | The Johns Hopkins University | Medication delivery system |
EP0266032A1 (en) | 1986-08-29 | 1988-05-04 | Beecham Group Plc | Modified fibrinolytic enzyme |
US5302390A (en) | 1987-07-01 | 1994-04-12 | Beecham Group Plc | Hybrid proteins of human plasminogen and human t-PA, pharmaceutical compositions and methods of treatment |
US5531219A (en) | 1994-11-04 | 1996-07-02 | Alliance Pharmaceutical Corp. | Use of liquid fluorocarbons to facilitate pulmonary drug delivery |
WO1998006426A1 (en) * | 1996-08-14 | 1998-02-19 | Gram Joergen Brodersen | Use of a plasminogen activator for the treatment of pulmonary disorders |
US20030113271A1 (en) * | 1997-01-29 | 2003-06-19 | University Technology Corporation | Formulations for pulmonary delivery |
KR20040090962A (ko) * | 2001-12-21 | 2004-10-27 | 엔바이로스크럽 테크놀러지스 코퍼레이션 | 망간 산화물의 전처리 및 재생 |
EP1589943A2 (en) * | 2003-01-09 | 2005-11-02 | Arizeke Pharmaceuticals, Inc. | Methods of treating lung diseases |
US20050169908A1 (en) | 2004-01-23 | 2005-08-04 | Kazunori Murakami | Use of aerosolized antithrombin to treat acute lung injury |
US20060198940A1 (en) | 2005-03-04 | 2006-09-07 | Mcmorrow David | Method of producing particles utilizing a vibrating mesh nebulizer for coating a medical appliance, a system for producing particles, and a medical appliance |
WO2007008825A2 (en) | 2005-07-11 | 2007-01-18 | Emory University | System and method for optimized delivery of an aerosol to the respiratory tract |
AU2006329199B8 (en) * | 2005-12-21 | 2014-01-09 | Solaeromed Inc. | Treatment of respiratory diseases |
SI22865A (sl) | 2008-09-25 | 2010-03-31 | Univerza@V@Ljubljani | Peptid uroaktivin kot aktivator encima urokinaze |
EP2361093A2 (en) * | 2008-11-26 | 2011-08-31 | Five Prime Therapeutics, Inc. | Compositions and methods for regulating collagen and smooth muscle actin expression by serpine2 |
DE102009031274A1 (de) * | 2009-06-30 | 2011-01-13 | Justus-Liebig-Universität Giessen | Liposomen zur pulmonalen Applikation |
WO2013029627A1 (en) * | 2011-08-29 | 2013-03-07 | Trifoilium Aps | Compositions and methods for treating or preventing radiation- or chemotherapy-induced pulmonary dysfunction |
-
2014
- 2014-11-04 US US15/034,019 patent/US20160279209A1/en not_active Abandoned
- 2014-11-04 WO PCT/US2014/063784 patent/WO2015066664A2/en active Application Filing
- 2014-11-04 CN CN201480060878.2A patent/CN105764488A/zh active Pending
- 2014-11-04 CA CA2928759A patent/CA2928759A1/en not_active Abandoned
- 2014-11-04 AU AU2014341862A patent/AU2014341862A1/en not_active Abandoned
- 2014-11-04 KR KR1020167012122A patent/KR20160078986A/ko not_active Application Discontinuation
- 2014-11-04 JP JP2016552448A patent/JP2016535782A/ja active Pending
- 2014-11-04 MX MX2016005720A patent/MX2016005720A/es unknown
- 2014-11-04 EP EP14857307.4A patent/EP3065705A4/en not_active Withdrawn
- 2014-11-04 PE PE2016000563A patent/PE20160789A1/es not_active Application Discontinuation
-
2016
- 2016-05-03 CL CL2016001062A patent/CL2016001062A1/es unknown
-
2019
- 2019-01-28 US US16/259,112 patent/US11033611B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN105764488A (zh) | 2016-07-13 |
KR20160078986A (ko) | 2016-07-05 |
MX2016005720A (es) | 2016-11-25 |
EP3065705A4 (en) | 2017-10-18 |
WO2015066664A2 (en) | 2015-05-07 |
AU2014341862A1 (en) | 2016-05-19 |
US20190255157A1 (en) | 2019-08-22 |
WO2015066664A3 (en) | 2015-09-17 |
CL2016001062A1 (es) | 2017-01-13 |
EP3065705A2 (en) | 2016-09-14 |
JP2016535782A (ja) | 2016-11-17 |
US20160279209A1 (en) | 2016-09-29 |
CA2928759A1 (en) | 2015-05-07 |
US11033611B2 (en) | 2021-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MD20140134A2 (ro) | Compuşi ai D-aminoacizilor pentru tratamentul bolilor hepatice | |
CR20150199A (es) | Análogos de 2´-cloro nucleósido para infección por vhc | |
DOP2014000049A (es) | Métodos para el tratamiento de hcv que comprenden al menos dos agentes antivirales de acción directa (daaas) y ribavirina pero no interferón | |
UA118248C2 (uk) | Інгібітори глюкозилцерамідсинтази | |
TN2015000091A1 (en) | Glucosylceramide synthase inhibitors | |
CL2011003003A1 (es) | Composicion tensioactiva reconstituida que comprende un polipeptido análogo a la proteína surfactante c nativa, un polipeptido análogo a la proteína surfactante b nativa, un fosfolipido monoinsaturado y un fosfolipido saturado, útil para el tratamiento del síndrome de dificultad respiratoria. | |
BR112016017690A2 (pt) | Tratamentos para acne resistente | |
MX2015009037A (es) | Enjuague nasal con miel. | |
BR112013027119A2 (pt) | novos conjugados ligante-droga (adcs) e uso dos mesmos | |
BR112015021888A2 (pt) | inibidores de dna-ik | |
CL2016000008A1 (es) | Tratamiento de lesiones inflamatorias de rosacea con ivermectina. | |
BR112017018209A2 (pt) | produtos terapêuticos de polipeptídeo e usos dos mesmos | |
AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
BR112015018270A2 (pt) | composições que compreendem 15-ohepa e métodos de uso das mesmas | |
CR20150455A (es) | Imidazopiridazinas sustituidas | |
BR112017006113A2 (pt) | combinações sinérgicas de auristatina | |
WO2013106689A8 (en) | Hcv ns3 protease inhibitors | |
CL2011000696A1 (es) | Particulas inhalables que comprenden una forma anhidra amorfa de tiotropio con un agente estabilizante que es lactosa; composicion farmaceutica; procedimiento para prepararlas que incluye secado por atomizacion; y su uso en asma y epoc | |
UY35848A (es) | Tienopirimidinas | |
BR112016029012A2 (pt) | método de tratamento de câncer de pulmão de células não pequenas e/ou câncer de pulmão de células pequenas usando compostos de tienotriazolodiazepina | |
PE20160789A1 (es) | Composiciones y metodos para admistracion de una enzima a las vias respiratorias de un sujeto | |
BR112016015997A2 (pt) | ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas? | |
BR112013003064A2 (pt) | agente profilático ou terapêutico para a esteato-hepatite não alcoólica | |
AR076520A1 (es) | Parasiticidas sanguineos. composicion | |
EA201301300A3 (ru) | Фармацевтическая композиция в форме пероральной суспензии, которая содержит фракцию флавоноида и ксантановую камедь |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |